Information  X 
Enter a valid email address

Xenetic Biosciences (XEN)

  Print      Mail a friend

Thursday 28 June, 2012

Xenetic Biosciences

Result of AGM

RNS Number : 3600G
Xenetic Biosciences PLC
28 June 2012
 



 

Xenetic Biosciences plc

('Xenetic' or 'the Company')

 

Result of AGM

 

Xenetic Biosciences plc (LSE: XEN.L), a bio-pharmaceutical company specialising in the development of high-value differentiated biological and vaccines and novel cancer drugs, held  its Annual General Meeting today at the offices of Pinsent Masons LLP at 30 Crown Place, London EC2A 4ES. All resolutions were duly passed.

 

 

Enquiries:

Xenetic Biosciences plc

+44 (0)20 3021 1500

M. Scott Maguire, Chief Executive Officer




Singer Capital Markets (NOMAD & Broker)

+44 (0)20 3205 7500

Claes Spång




Walbrook PR

+44 (0)20 7933 8780

Paul McManus (Media Enquiries)

paul.mcmanus@walbrookpr.com

Paul Cornelius (Investor Enquiries)

paul.cornelius@walbrookir.com

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RAGBKFDDKBKDFAB